$16.98
2.13%
Nasdaq, Oct 02, 04:00 pm EDT. Closed.
ISIN
US3968791083
Symbol
GLSI

Greenwich LifeSciences Inc Stock price

$16.98
+1.24 7.88% 1M
-5.84 25.59% 6M
-4.03 19.18% YTD
+6.33 59.44% 1Y
+8.04 89.93% 3Y
-19.78 53.81% 5Y
+11.23 195.30% 10Y
+11.23 195.30% 20Y
Nasdaq, Closing price Fri, Oct 02 2026
-0.37 2.13%
ISIN
US3968791083
Symbol
GLSI
Industry

Is Greenwich LifeSciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
$249.2m
Enterprise Value
$240.4m
Net debt
positive
Cash
$8.9m
Shares outstanding
14.7m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
negative | negative
P/B
79.9
Financial Health
Equity Ratio
5.7%
Return on Equity
-5,480.8%
ROCE
-700.9%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$6.7m | -
SBC as % of FCF
-
SBC Growth 1Y
-26.4%
Share Count Growth 1Y
9.0%
Shareholder Yield
-9.0%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
-
EBIT
$-21.9m
Net Income
$-21.7m
Free Cash Flow | ex SBC
$-12.5m | $-19.2m
Growth
Revenue | estimate
- | -
EBITDA
-
EBIT
-20.5%
Net Income
-20.5%
Free Cash Flow
-46.9%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-1.5
FCF per Share
$-0.9
Short interest
21.3%
Employees
6
Rev per Employee
$0.0

Greenwich LifeSciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Greenwich LifeSciences Inc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Greenwich LifeSciences Inc forecast:

Buy
88%
Hold
13%

Financial data from Greenwich LifeSciences Inc

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 1.99 1.99
44% 44%
-
- Research and Development Expense 20 20
37% 37%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -22 -22
21% 21%
-
Net Profit -22 -22
21% 21%
-

In millions USD.

Don't miss a Thing! We will send you all news about Greenwich LifeSciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Greenwich LifeSciences Inc Stock News

Negative
Market Watch
●
about one month ago
Certain stocks are such poor bets that they are likely to lose ground even in bull markets.
Neutral
GlobeNewsWire
●
about 2 months ago
STAFFORD, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the share...
Neutral
GlobeNewsWire
●
2 months ago
STAFFORD, Texas, July 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the regulatory approval to expand FLAMINGO-01 into the United Kingdom.
More Greenwich LifeSciences Inc News

Company Profile

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Head office United States
CEO Mr. Patel
Employees 6
Founded 2006
Website greenwichlifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today